A Study for Tysabri Participant Preference

NCT05304520 · clinicaltrials.gov ↗

COMPLETED

Status

318

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis (RRMS)

Interventions

DRUG: Natalizumab

Sponsor

Biogen